Literature DB >> 33646444

Cerebrospinal fluid diversion and outcomes for lung cancer patients with leptomeningeal carcinomatosis.

Yan-Hua Su1, Chi-Lu Chiang2,3, Huai-Che Yang1,2, Yong-Sin Hu2,4, Yu-Wei Chen1, Yung-Hung Luo2,3, Ching-Jen Chen5, Hsiu-Mei Wu2,4, Chung-Jung Lin2,4, Cheng-Chia Lee6,7,8.   

Abstract

OBJECTIVE: To investigate the outcomes of cerebrospinal fluid (CSF) diversion in lung cancer patients with leptomeningeal carcinomatosis (LMC).
METHODS: A retrospective review of consecutive lung cancer patients with LMC suffering from increased intracranial pressure (IICP) and hydrocephalus between February 2017 and February 2020. We evaluated the survival benefit of CSF diversion surgery and assessed the outcomes of treatments administered post-LMC in terms of overall survival and shunt-related complications.
RESULTS: The study cohort included 50 patients (median age: 59 years). Ventricular peritoneal (VP) shunts were placed in 33 patients, and lumbar peritoneal (LP) shunts were placed in 7 patients. Programmable shunts were placed in 36 patients. Shunt adjustment was performed in 19 patients. Kaplan-Meier analysis revealed that shunt placement increased overall survival from 1.95 months to 6.21 months (p = 0.0012) and increased Karnofsky Performance Scores (KPS) from 60 to 70. Univariate analysis revealed no difference between VP or LP shunts in terms of survival. No differences in post-shunt systemic treatments (tyrosine kinase inhibitors (TKIs) or systemic treatments) were observed in overall survival. Shunt-related complications were noted in 7 patients, including shunt obstruction (n = 4), infection (n = 1), and over-drainage (n = 2).
CONCLUSION: CSF diversion (VP or LP shunt) appears to be an effective and safe treatment for lung cancer patients with LMC and hydrocephalus. Programmable shunts should be considered for complex cases, which commonly require pressure adjustments as the disease progresses.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, AT part of Springer Nature.

Entities:  

Keywords:  Brain metastasis; EGFR mutation; Hydrocephalus; Leptomeningeal carcinomatosis; Lung cancer; Shunt

Mesh:

Year:  2021        PMID: 33646444     DOI: 10.1007/s00701-021-04763-w

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  19 in total

1.  High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.

Authors:  Takahisa Kawamura; Akito Hata; Jumpei Takeshita; Shiro Fujita; Michio Hayashi; Keisuke Tomii; Nobuyuki Katakami
Journal:  Cancer Chemother Pharmacol       Date:  2015-04-29       Impact factor: 3.333

Review 2.  Leptomeningeal carcinomatosis.

Authors:  S A Grossman; M J Krabak
Journal:  Cancer Treat Rev       Date:  1999-04       Impact factor: 12.111

Review 3.  Leptomeningeal metastasis.

Authors:  Marc C Chamberlain
Journal:  Curr Opin Oncol       Date:  2010-11       Impact factor: 3.645

4.  Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations.

Authors:  F Hsu; A De Caluwe; D Anderson; A Nichol; T Toriumi; C Ho
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

5.  Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment.

Authors:  Ticiana Leal; Julie E Chang; Minesh Mehta; H Ian Robins
Journal:  Curr Cancer Ther Rev       Date:  2011-11

6.  Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma.

Authors:  Ryota Kanemaru; Yoshiteru Morio; Hidenori Takekawa; Hitomi Jo; Fumiko Kasuga; Ryo Koyama; Satomi Shiota; Tetsutaro Nagaoka; Kazuhisa Takahashi
Journal:  Respir Investig       Date:  2016-06-06

7.  Epidermal Growth Factor Receptor Mutation Detection in Cerebrospinal Fluid of Lung Adenocarcinoma Patients with Leptomeningeal Metastasis.

Authors:  Ruofan Huang; Mengxi Ge; Xinli Zhou; Xiaoyu Ji; Li Liao; Xiaohua Liang; Qiong Zhan
Journal:  Cancer Biother Radiopharm       Date:  2018-11-16       Impact factor: 3.099

8.  Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease.

Authors:  Surein Arulananda; Hongdo Do; Gareth Rivalland; Zoe Loh; Ashan Musafer; Eddie Lau; Paul Mitchell; Alexander Dobrovic; Thomas John
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

9.  Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.

Authors:  Xueyang Hu; Wenjun Chen; Xiaoqiu Li; Chenchen Zhao; Congjun Zhang; Fuxing Xiong; Hongyang Wu
Journal:  Ann Palliat Med       Date:  2019-11

10.  Ventriculoperitoneal shunting versus endoscopic third ventriculostomy in the treatment of patients with hydrocephalus related to metastasis.

Authors:  David D Gonda; Teddy E Kim; Peter C Warnke; Ekkehard M Kasper; Bob S Carter; Clark C Chen
Journal:  Surg Neurol Int       Date:  2012-08-27
View more
  1 in total

Review 1.  State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan.

Authors:  Yung-Hung Luo; Kung-Hao Liang; Hsu-Ching Huang; Chia-I Shen; Chi-Lu Chiang; Mong-Lien Wang; Shih-Hwa Chiou; Yuh-Min Chen
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.